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Abstract
Background: 5a-reductase 1 (5aR1) and 5a-reductase 2 (5aR2) convert testosterone into the more potent androgen
dihydrotestosterone. 5aR2 is the main isoenzyme in normal prostate tissue; however, most prostate tumors have increased
5aR1 and decreased 5aR2 expression. Previously, finasteride (5aR2 inhibitor) treatment begun 3 weeks post-tumor
implantation had no effect on Dunning R3327-H rat prostate tumor growth. We believe the tumor compensated for
finasteride treatment by increasing tumor 5aR1 expression or activity. We hypothesize that finasteride treatment would not
significantly alter tumor growth even if begun before tumor implantation, whereas dutasteride (5aR1 and 5aR2 inhibitor)
treatment would decrease tumor growth regardless of whether treatment was initiated before or after tumor implantation.
Methodology/Principal Findings: Sixty 8-week-old male nude mice were randomized to Control, Pre- and Post-Finasteride,
and Pre- and Post-Dutasteride (83.3 mg drug/kg diet) diet groups. Pre- and post-groups began their treatment diets 1–2
weeks prior to or 3 weeks after subcutaneous injection of 1610
5 WPE1-NA22 human prostate cancer cells, respectively.
Tumors were allowed to grow for 22 weeks; tumor areas, body weights, and food intakes were measured weekly. At study’s
conclusion, prostate and seminal vesicle weights were significantly decreased in all treatment groups versus the control;
dutasteride intake significantly decreased seminal vesicle weights compared to finasteride intake. No differences were
measured in final tumor areas or tumor weights between groups, likely due to poor tumor growth. In follow-up studies,
proliferation of WPE1-NA22 prostate cancer cells and parent line RWPE-1 prostate epithelial cells were unaltered by
treatment with testosterone, dihydrotestosterone, or mibolerone, suggesting that these cell lines are not androgen-
sensitive.
Conclusion: The lack of response of WPE1-NA22 prostate cancer cells to androgen treatment may explain the inadequate
tumor growth observed. Additional studies are needed to determine whether finasteride and dutasteride are effective in
decreasing prostate cancer development/growth.
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Introduction
Prostate cancer is the most commonly diagnosed malignancy in
men, estimated to account for nearly 30% of cancer cases in 2011
[1]. Prostate tumor growth is commonly stimulated by androgens.
Testosterone, the main circulating androgen, is converted by the
isoenzymes 5a-reductase 1 and 5a-reductase 2 into the more
potent dihydrotestosterone, which binds with up to ten-fold higher
affinity to the androgen receptor than testosterone [2,3]. 5a-
reductase 1 is the major isoenzyme in human liver and nongenital
skin, whereas 5a-reductase 2 is the major isoenzyme in the
prostate, epididymis, seminal vesicle, and genital skin [4].
Inhibiting androgen production and/or blocking its action are
common approaches for combatting prostate cancer [5]. Most
studies report increased 5a-reductase 1 and decreased 5a-
reductase 2 mRNA expression or activity in prostate cancer [6–
9]. Others have reported increased 5a-reductase 1 mRNA
expression and no significant changes in 5a-reductase 2 mRNA
expression in prostate cancer versus normal tissue [10], increased
expression of both isoenzymes in prostate cancer [5], or loss of
expression of both isoenzymes in metastatic prostate cancer [11].
Two 5a-reductase inhibitors, finasteride (5a-reductase 2 inhibitor)
and dutasteride (5a-reductase 1 and 2 inhibitor), are commonly
used to treat benign prostatic hyperplasia (BPH) [12]. These 5a-
reductase inhibitors also could be used to prevent or treat prostate
cancer by reducing dihydrotestosterone levels [13].
In support of this possibility, finasteride decreased prostate
cancer prevalence by 24.8% in the Prostate Cancer Prevention
Trial (PCPT) [14]. Similarly, in the Reduction by Dutasteride of
Prostate Events (REDUCE) trial, dutasteride reduced prostate
cancer incidence by 23% [15]; however, based on the results from
these trials, the Food and Drug Administration (FDA) recently
revised the safety information for both drugs to state that the drugs
increase patients’ risk for developing high-grade prostate cancer
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growth of Dunning R-3327H rat prostate tumors [17]. In nude
mice bearing LNCaP human prostate cancer xenografts, both
finasteride and dutasteride reduced tumor growth, although
dutasteride was more effective at an equimolar dose [17]. In rats,
finasteride significantly decreased androgen-sensitive tissue
weights, but did not decrease Dunning R-3327H tumor growth
[18].
In these animal studies, finasteride and dutasteride administra-
tion began after tumors were established; finasteride administra-
tion initiated before tumor implantation may be more efficacious.
On the other hand, regardless of when finasteride treatment is
initiated, prostate cancer cells may compensate for 5a-reductase 2
inhibition by increasing 5a-reductase 1 expression and/or activity;
thus, the dual inhibitory effect of dutasteride may offer an
advantage over finasteride. We examined the effect of finasteride
and dutasteride diets begun 1 week before or 3 weeks after
subcutaneous injection of WPE1-NA22 human prostate cancer
cells into the rear flanks of male nude mice. We used WPE1-NA22
prostate cancer xenografts because these human cancer cells can
be cultured in vitro, yet form noninvasive tumors with growth rates
and pathology similar to the Dunning R-3327H tumor [19,20].
Materials and Methods
The Institutional Animal Care and Use Committee (IACUC) of
Kansas State University approved all animal procedures (protocol
2794).
Cell Lines
WPE1-NA22 prostate cancer and RWPE-1 prostate epithelial
cells (ATCC, Manassas, VA) were cultured in serum-free
keratinocyte media containing bovine pituitary extract and
epidermal growth factor (GIBCO Invitrogen, Carlsband, CA).
For the animal study, WPE1-NA22 cells were cultured in
75 cm
2 flasks (Fisher Scientific, Pittsburg, PA), removed with
trypsin (Sigma-Aldrich, St. Lo u i s ,M O ) ,a n dc e n t r i f u g e df o r
7 minutes at 1306ga t3 7 uC. Supernatant was removed and cells
were reconstituted in Matrigel
TM (BD Biosciences, Franklin
Lakes, NJ) at a concentration of 5,000 cells/mL. Twenty
microliters of Matrigel
TM containing ,1610
5 WPE1-NA22
cancer cells was injected into each rear flank of nude mice using
a Hamilton syringe holder (Hamilton, Reno, NV) fitted with a
1 mL syringe and a 25 gauge 5/8-in. needle (both from BD
Biosciences).
Animals, Study Diets and Design
Two cohorts of 30 (60 total) 8-week-old male nude mice
(Charles Rivers, Wilmington, MA) were individually housed in
sterile conditions. Mice were monitored daily, weighed weekly,
and provided diets and water ad libitum. AIN93-G treatment diets
(Research Diets, New Brunswick, NJ) contained dutasteride
(provided by GlaxoSmithKline Pharmaceuticals, Research Trian-
gle Park, NC) and finasteride (Kemprotec, Middlesbrough, UK) at
83.3 mg/kg of diet, designed to provide ,10 mg drug/kg body
weight, which was the middle dutasteride dose used by Xu and
colleagues [17]. After receipt, mice were acclimated for 1 week
before being randomized to Control, Pre-Finasteride, Post-
Finasteride, Pre-Dutasteride, and Post-Dutasteride groups
(n=10–12, Figure 1). Five mice did not complete the study for
health reasons unrelated to tumor growth. Pre- and post-groups
began their treatment diets 1–2 weeks prior or 3 weeks after
WPE1-NA22 cell injection, respectively. The three weeks after
injection timepoint was chosen because Canene-Adams and
colleagues initiated finasteride treatment at the same point [18].
The study was terminated 22 weeks post-tumor implantation.
Mice were euthanized by CO2 inhalation and blood was
immediately drawn via cardiac puncture and centrifuged for
1 minute at 20006g to obtain serum. Tissues were dissected, flash
frozen in liquid nitrogen, and stored in a freezer at 280uC.
Tumor area was calculated using the formula for area of an
ellipse: area = p*(length/2)*(width/2). The average tumor area in
a group was calculated by summing the individual tumor areas for
the group, then dividing by the total number of tumor sites in the
group. Zeros were recorded for tumor sites without measureable
tumors.
In Vitro Androgen Treatment and Cell Viability
WPE1-NA22 cells (passage number #7) and RWPE-1 cells
(passage number #6) were plated at 10,000 cells per well in 96-
well plates (Fisher Scientific, Pittsburg, PA). Twenty-four hours
after plating, both cell lines were treated with testosterone
(0.1 nM–30 nM), dihydrotestosterone (0.03 nM–100 nM, both
from Sigma Aldrich, St. Louis, MO), and synthetic androgen
mibolerone (0.01 nM–20 nM, PerkinElmer, Waltham, MA) in
0.1% ethanol. Media and androgen treatments were prepared
daily and changed every 24 hours during the 5-day treatment
period. Cell viability was quantified using the CellTiter 96
AQueous One Solution Assay (Promega Corporation, Madison,
WI) with a Bio-Tek uQuant Plate reader (BioTek, Winooski, VT).
Results presented are from 4 replicates of the experiments.
Statistical Analysis
Data was analyzed using SAS 9.2 (SAS Institute Inc., Cary,
North Carolina), with p,0.05 considered statistically significant.
ANCOVA with cohort as the covariate was used to initially
analyze the animal study results. The covariate was removed
because it did not account for a significant amount of variance in
all analyses, and ANOVA with Tukey’s test was used on pooled
data from the two cohorts. Natural logs were used to transform
data when data did not meet model assumptions. Kruskal Wallis
non-parametric one-way ANOVA was used for tumor incidence.
Androgen treatment cell viability data were analyzed using
ANOVA with Dunnett’s test.
Figure 1. Animal study design: After receipt, mice were
acclimated for 1 week then randomized into Control, Pre-
Finasteride, Post-Finasteride, Pre-Dutasteride, and Post-Du-
tasteride groups (n=12). Pre- and post-groups began their
treatment diets 1–2 weeks prior or 3 weeks after WPE1-NA22 cell
injection, respectively. The study was terminated 22 weeks post-tumor
implantation.
doi:10.1371/journal.pone.0029068.g001
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Final body weights of the Pre-Finasteride group were signifi-
cantly higher than the control (Table 1, p,0.05) despite no
differences in daily food intake or food efficiency (data not shown)
among the groups. Tumor incidence was high, 86.4% to 95.5%,
with no difference between groups (Figure 2). No difference was
found in tumor weights and tumor areas between groups (Table 1
and Figure 3), likely a result of poor tumor growth. The largest
average tumor diameter in any group was 4.33 mm. Despite not
altering tumor growth, both finasteride and dutasteride signifi-
cantly decreased prostate and seminal vesicle weights as a
percentage of body weight (p,0.05). In addition, there was a
significant decrease in seminal vesicle weights in dutasteride
groups versus finasteride groups (Table 1).
These reductions in androgen-sensitive tissues suggest that
finasteride and dutasteride were exerting their anti-androgenic
action. One explanation for the poor growth is that WPE1-NA22
cells are not androgen-sensitive like their parent RWPE-1 human
prostate epithelial cells [21]. Thus, WPE1-NA22 and RWPE-1
cells were treated with varying concentrations of testosterone,
dihydrotestosterone, and the synthetic androgen mibolerone. We
found no difference in cell numbers in either cell line when treated
with varying concentrations of androgens (Figures 4 and 5).
Discussion
In this study, we examined the effects of two 5a-reductase
inhibitors, finasteride and dutasteride, pre- and post-tumor
injection on the growth of WPE1-NA22 xenografts in nude mice.
Tumor incidence was high for all groups ranging from 86.4% to
95.5%, similar to the ,92–99% reported in previous Dunning R-
3327H rat prostate cancer studies [18,22]. The poor growth of
WPE1-NA22 xenografts in nude mice was a surprise given that the
xenograft tumor volume was previously reported to be 0.2 cm
3 7
weeks after implantation [20]. Back-calculating this is a tumor
diameter of ,7.26 mm, which is much larger than we observed at
any time during our study.
One methodological difference between studies that likely
contributed to the differences in tumor growth is the difference
in the number of WPE1-NA22 cancer cells injected into the flanks
of mice. Webber and colleagues subcutaneously injected 5610
5
WPE1-NA22 cells, five times more cells than we injected in this
study [20]. Fewer cells were injected because of concerns that the
tumor growth would be too rapid, given the size reported at 7
weeks compared with Dunning R-3327H tumors that are not
palpable until 9–10 weeks post-tumor implantation [18,22]. Two
other possible explanations for the poor growth of WPE1-NA22
xenografts are that the nude mice were generating an immune
Figure 2. Tumor incidence (n =20–24) in tumor sites. Zeros were
recorded for tumor sites without a tumor; no significant differences
between groups.
doi:10.1371/journal.pone.0029068.g002
Figure 3. Tumor area (n=20–24) of tumor sites. Zeros were
recorded for tumor sites without tumors; no significant differences
between groups.
doi:10.1371/journal.pone.0029068.g003
Table 1. Final body weights, tumor incidence, tumor weights, seminal vesicle weights as a percentage of body weight, and
prostate weights as percentage of body weight
1.
Groups
Final body weights
(g, n=10–12)
Final tumor
incidence
(%, n= 20–24)
Tumor weights
(mg, n= 20–24)
Seminal vesicle
weights (% body
weight, n=10–12)
Prostate weights
(% body weight,
n=10–12)
Control 30.6 6 0.6
a 87.5 35 6 7 0.92 6 0.05
a 0.42 6 0.05
a
Pre-Finasteride 33.2 6 0.7
b 86.4 25 6 3 0.34 6 0.02
b 0.23 6 0.02
b
Post-Finasteride 30.9 6 0.8
a 95.5 30 6 4 0.38 6 0.03
b 0.276 0.02
b
Pre-Dutasteride 29.4 6 0.9
a 95.0 36 6 8 0.21 6 0.01
c 0.26 6 0.02
b
Post-Dutasteride 30.2 6 0.6
a 86.4 22 6 2 0.23 6 0.02
c 0.23 6 0.03
b
1Data are means 6 SEM; values with different letters are statistically different.
doi:10.1371/journal.pone.0029068.t001
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androgen-sensitive, so androgens did not stimulate their growth.
We set out to investigate the latter possibility by treating WPE1-
NA22 cells and their parent cell line, RWPE-1 human prostate
epithelial cells with a variety of concentrations of three androgens.
Previously, growth of RWPE-1 cells increased in a dose-dependent
manner when treated with mibolerone at doses of 0.01–10 nM
[21]. Androgen concentrations used in our in vitro studies were
based on several studies that examined the proliferative response
to the three androgens [21,23–25]. Physiological intraprostatic
levels of both testosterone (,0.2 nM–0.7 nM) [26] and dihydro-
testosterone (5 nM–18 nM) [17,27,28] in humans fall within the
range of concentrations used. For mibolerone, we used the
concentrations by Bello and colleagues [21], but we also doubled
their top concentration for our highest concentration.
Interestingly, we found no difference in cell numbers in either
cell line in response to various concentrations of respective
androgen treatments. We tried to repeat the methodology of Bello
and colleagues; the only difference being that we used the MTS
assay whereas they used a methylene blue assay for quantitating
cell viability [21].
The lack of androgen sensitivity of both cells may explain the
observed poor tumor growth. Further supporting our findings are
that nuclear androgen receptor, nuclear 5a-reductase 2, and
cytosolic 5a-reductase 1 protein levels are undetectable in RWPE-
1 cells [29]. Cell lines derived from this parent line likely have
similar levels of these key androgen metabolism/action proteins.
Furthermore, both cell lines are grown in media without fetal
bovine serum and exogenous androgens, meaning it is androgen-
free. Taken together, these results should be considered before
using or interpreting results from RWPE-1 and its carcinogenic
derived cell lines.
Another surprising result was the significantly higher body
weight in the Pre-Finasteride group without an alteration in food
intake or food efficiency. Based on the trend in growth in the Pre-
Finasteride group, we believe the group was heavier at
randomization even though the differences in body weights were
not significant at the time. The Pre-Finasteride group was already
significantly heavier than the Pre-Dutasteride group 1 week after
randomization despite negligible differences in food intake (the
Pre-Dutasteride group consumed numerically more during that
week), which supports our belief. Finasteride has been found to
slightly increase weight gain in men with prostate cancer [30], but
long-term intake did not increase the body weights of rats [31].
Diets in all treatment groups were well tolerated with no noted
adverse effects.
The magnitude of decrease of prostate and seminal vesicles
weights in response to dutasteride and finasteride were similar to
those reported previously [18,32,33]. We also found a significant
decrease in seminal vesicle weights in dutasteride groups versus
finasteride groups. To the best of our knowledge, we are the first to
report that dutasteride results in a greater magnitude of decrease
in seminal vesicles weights than finasteride. Mice in our study
consumed approximately 13 mg/kg/day of finasteride or dutaste-
ride, which is greater than the 5 mg/kg/day of finasteride used by
Canene and colleagues [18] but similar to the middle dutasteride
dose used by Xu and colleagues [17].
In summary, although we did not see an effect of both inhibitors
on the growth of WPE1-NA22 xenograft in vivo, results from the
prostate and seminal vesicles indicate that the inhibitors were
effective in inhibiting their respective 5a-reductase enzyme(s).
Further research in different models will be required to answer our
research question; however, our results question the tumorigenic-
ity of WPE1-NA22 cells in nude mice and the androgen-sensitivity
of WPE1-NA22 and RWPE-1 cells.
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Figure 4. RPWE-1 (10,000 cells/well) cell viability was not
altered by daily treatment of testosterone (0.1 nM–30 nM),
dihydrotestosterone (0.03 nM–100 nM), or mibolerone
(0.01 nM–20 nM) after a 5-day treatment period; no significant
treatment effects.
doi:10.1371/journal.pone.0029068.g004
Figure 5. WPE1-NA22 (10,000 cells/well) cell viability was not
altered by daily treatment of testosterone (0.1 nM–30 nM),
dihydrotestosterone (0.03 nM–100 nM), or mibolerone
(0.01 nM–20 nM) after a 5-day treatment period; no significant
treatment effects.
doi:10.1371/journal.pone.0029068.g005
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